Novartis and Microsoft have announced the strategic partnership for funding the artificial intelligence lab to transform the medicine using the data and artificial intelligence. The goal of this lab is to accelerate the discovery and development of medicines using artificial intelligence.
This strategic alliance is focused at two areas:
AI Empowerment: Microsoft helps Novartis in collaborating the datasets to enable Novartis to prepare for the next level challenges. The target is to make the datasets available at the desk of every employee
AI exploration: To tackle computation challenges in the fields of generative chemistry, image segmentation & analysis
Related: Novartis SEG101 (crizanlizumab) received priority review from US FDA
Vas Narasimhan, CEO of Novartis in a statement quoted that “As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend patients’ lives. Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world.”
In addition, Satya Nadella, CEO of Microsoft quoted that “Our strategic alliance will combine Novartis' life sciences expertise with the power of Azure and Microsoft AI. Together, we aim to address some of the biggest challenges facing the life sciences industry today and bring AI capabilities to every Novartis employee so they can unlock new insights as they work to discover new medicines and reduce patient costs.”